StoneX Group
IRD icon

StoneX Group’s Opus Genetics IRD Stock Holding History

StoneX Group’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$60.7K Buy
+15,775
New +$65.5K ﹤0.01% 1574

Other funds holding IRD

Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $184B AUM 51.71% 1-Year Est. Return
Miller Financial Services
Miller Financial Services Marshall, Michigan $132M AUM 10.64% 1-Year Est. Return
Empirical Wealth Management
Empirical Wealth Management Seattle, Washington $7.38B AUM 22.9% 1-Year Est. Return
James Investment Research
James Investment Research Alpha, Ohio $936M AUM 24.49% 1-Year Est. Return
SPAL
StoneRidge PMG Advisors, LLC Radnor, Pennsylvania $142M AUM
Sanders Morris Harris
Sanders Morris Harris Houston, Texas $755M AUM 11.28% 1-Year Est. Return
First City Capital Management
First City Capital Management Savannah, Georgia $204M AUM 20.28% 1-Year Est. Return
Concurrent Investment Advisors
Concurrent Investment Advisors Tampa, Florida $14.5B AUM 24.52% 1-Year Est. Return

StoneX Group's IRD Position: Q3 2026 in Review

StoneX Group opened a new position in Opus Genetics (IRD) in Q3 2026: 15,775 shares worth $60.7K. The stake represents ﹤0.01% of the portfolio and ranks #1574 among its holdings.

23 funds tracked by Wall St. Rank hold IRD as of Q3 2026.

  • StoneX Group held 15,775 shares of Opus Genetics worth $60.7K as of Q3 2026.
  • Opus Genetics was a new StoneX Group position in Q3 2026.
  • Opus Genetics made up ﹤0.01% of StoneX Group's portfolio in Q3 2026, its #1574 holding.
  • 23 funds tracked by Wall St. Rank held Opus Genetics as of Q3 2026.

Based on StoneX Group's 13F filing for Q3 2026, filed 3 Nov 2026.